Abstract:8546 Background: Mefatinib is an irreversible and highly effective EGFR and HER2 dual inhibitor. Although EGFR tyrosine kinase inhibitors are standard 1st line therapy for EGFR mutated non-small cell lung cancer (NSCLC), co-mutations, such as TP53 are associated with shorter PFS of EGFR TKI. Methods: Patients newly diagnosed with EGFR exon 19 deletion (19 del) or exon 21 L858R mutant (L858R), stage IIIB/IV NSCLC were enrolled and randomized at 2:1 ratio to receive mefatinib 60 mg PO QD or gefitinib 250 mg PO QD; The primary endpoint of the study was progression-free survival (PFS) per independent review committee (IRC). Archival tumor samples were analyzed using a 150 genes next-generation sequencing panel for biomarker analysis. Results: 336 eligible patients were assigned to receive mefatinib (n = 223) or gefitinib (n = 113). The median PFS of mefatinib was longer than gefitinib (13.73 vs. 9.66 months, hazard ratio [HR] = 0.68, P= 0.0024) and even longer in L858R subgroup (13.73 vs. 8.28 months, HR = 0.55). The data on overall survival (OS) were immature at the cut-off date ( < 40% events). 288 patients (189 in mefatinib and 99 in gefitinib) had available tumor samples for exploratory biomarker analysis. TP53 mutations were the most common disruptive concurrent alterations (45%). In patients with co-occurring disruptive mutations, mefatinib showed significant improvement in PFS compared to gefininib (12.55 vs 9.56 months, HR = 0.56, P= 0.0005; 12.55 vs 12.39 months, HR = 0.65, P= 0.0753 in 19del; and 13.70 vs 8.28 months, HR = 0.44, P= 0.0004 in L858R); Similarly, OS benefit of mefatinib was observed compared to gefitinib (not reached vs 26.68 months, HR = 0.54, P= 0.0045; not reached vs not reached, HR = 0.75, P= 0.4121 in 19del; and not reached vs 20.01 months, HR = 0.40, P= 0.0006 in L858R). Mefatinib had a favorable safety profile, with only 5.8% of patients experiencing dose reduction and less than 5% discontinuing treatment. Conclusions: Mefatinib is a new frontline option for EGFRmutant NSCLC. Co-occurring disruptive mutations caused decreased therapeutic efficacy of gefitinib, but had minimal impact on the PFS and OS of mefatinib. Comparing to gefitinib, PFS and OS improvements of mefatinib were most pronounced in patients with EGFR L858R mutation, especially those with disruptive co-occurring mutations. EGFR 19del or L858R mutation alone may not be sufficient to inform optimized front line therapies. Further studies are warranted to verify functional concurrent mutations for a better individualized precision medicine. Clinical trial information: CTR20192297.

Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.

Combined Targeting Of The Estrogen Receptor And The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects

Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib

Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

HER2 Overexpression Reverses the Relative Resistance of EGFR-mutant H1975 Cell Line to Gefitinib.

Mefatinib As First-Line Treatment of EGFR Sensitizing Mutation-Positive Non-Small-cell Lung Cancer: A Phase III Efficacy and Biomarker Study.

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1

Fruquintinib with Gefitinib As First-Line Therapy in Patients Carrying EGFR Mutations with Advanced Non-Small Cell Lung Cancer: a Single-Arm, Phase II Study

MiR-142-5p Reverses the Resistance to Gefitinib Through Targeting HOXD8 in Lung Cancer Cells.

Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant

Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor α to vinblastine and vinorelbine

Combined Tamoxifen and Gefitinib in Non-Small Cell Lung Cancer Shows Antiproliferative Effects.

β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer

Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression.

Silencing Med1 Sensitizes Breast Cancer Cells To Pure Anti-Estrogen Fulvestrant In Vitro And In Vivo

Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review

IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ERα stability